Table 1

Characteristics of study population
Clinical parameters Breast cancer patients (n=307) Healthy controls (n=396)
Age (median) in years k 56 (22-91) 45 (18-88)
Menopausal status n=287
Premenopausal 88 (31%)
Postmenopausal 179 (62%)
Perimenopausal 20 (7%)
Unknown 20
Tumor growth n=303
Invasive 275 (91%)
Non-invasive 28 (9%)
Unknown 4
Localization n=306
Right 123 (40%)
Left 173 (57%)
Bilateral 10 (3%)
Unknown 1
Type a, b n=255
Ductal 189 (74%)
Lobular 34 (13%)
Other types 32 (13%)
Unknown 21
Tumor size (T) a, b, c n=229
T1 (< 2 cm) 142 (62%)
T2 (>/= 2 cm – 5 cm) 76 (33%)
T3 (</= 5 cm) 6 (3%)
T4 (infiltration of the chest 5 (2%)
wall/skin)
Unknown 24
Nodal status (N) b, c n=250
N+ 75 (30%)
N- 175 (70%)
Unknown 36
Distant metastases (M) n=292
M+ 16 (5%)
osseous 10 (3%)
M- 276 (95%)
Unknown 15
Tumor grading (G) n=245
G1 16 (6%)
G2 161 (63%)
G3 78 (31%)
Unknown 49
Estrogen receptor (ER) d n=275
ER+ 224 (81%)
ER- 51 (19%)
Unknown 32
Progesterone receptor (PR) b, d n=274
PR+ 193 (70%)
PR- 81 (30%)
Unknown 32
Her-2 a, b, e n=208
Her2+ 42 (20%)
Her2- 166 (80%)
Unknown 67
Ki67 a, b, f n=187
Ki67+ 84 (45%)
Ki67- 103 (55%)
Unknown 88
CEA f n=107
CEA+ 26 (24%)
CEA- 81 (76%)
Unknown 200
CA15-3 h n=215
CA15-3+ 81 (38%)
CA15-3- 134 (62%)
Unknown 92
Body mass index (BMI) m n=219
BMI < 28 150 (68%)
BMI >/= 28 69 (32%)
Unknown 88
Subgroup a, i n=249
Triple negative 22 (9%)
Non triple negative 227 (91%)
Unknown 30
Subgroup a, j n=262
Risk group 18 (7%)
Non risk group 244 (93%)
Unknown 15

aOnly invasive tumors are included; bBilateral tumors are only included if both sides had the same result; cExclusion of cases with neoadjuvant chemotherapy; dImmunoreactive score: 0: negative, 1-12: positive; eHer2 = human epidermal growth factor receptor 2; immunoreactive score 0-2 (FISH negative): negative, 2 (FISH positive)-3: positive; fKi67 = marker for proliferation (< 13%: negative, >/= 13%: positive); gCEA = carcinoembryonic antigen (tumor marker, < 3 ng/ml: negative, >/= 3 ng/ml: positive); hCA15-3 = tumor marker (< 21 U/ml: negative, >/= 21 U/ml: positive); iTriple negative = ER, PR and Her2 negative; jRisk group: T >/= 2, G3, ER negative; FISH = fluorescence in situ hybridization; ksignificant difference (p< 0.001), age-adjusted statistical analysis performed; mBMI >/= 28 was defined as overweight in order to age-adjustment [https://www.uni-hohenheim.de/wwwin140/info/interaktives/bmi.htm webcite].

Ney et al.

Ney et al. BMC Cancer 2013 13:40   doi:10.1186/1471-2407-13-40

Open Data